Please assess the completion status of the following clinical trial:

Trial Title: Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cirrhosis defined by clinical, laboratory or ultrasonographic findings~* Child-Pugh \> 8~* Sepsis defined by the presence of proved or suspected infection with two of the four SIRS (systemic inflammatory response syndrome) criteria (Wong F, et al. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005)~* Creatinine \< 160 µmol/L~* Written informed consent~* Absence of the exclusion criteria~Exclusion Criteria:~* Spontaneous bacterial peritonitis~* Difficult to treat infections such as : endocarditis, septic arthritis, osteomyelitis~* Heart insufficiency (YHA III-IV)~* Digestive bleeding during the week preceding the study~* Septic shock~* Hepatocellular carcinoma : stage D~* Use of antibiotics during the week preceding the study, except noroxin used for long-term antibioprophylaxy~* Diseases which can influence the short term survival

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Usual treatment (Type: NO_INTERVENTION): intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
- Human Albumin (Type: EXPERIMENTAL): 1,5g/kg on first day and 1g/kg on third day.

Based on this trial design, predict the completion outcome and termination type (if applicable).